You are here

Article Text

Article menu
Download PDFPDF
Adverse events with biologics
The British Society for Rheumatology Biologics Register
  1. K Watson1,
  2. D Symmons1,
  3. I Griffiths2,
  4. A Silman1
  1. 1arc Epidemiology Research Unit, Manchester University Medical School, Manchester, UK
  2. 2British Society for Rheumatology, London, UK
  1. Correspondence to:
    A Silman
    alan.silmanmanchester.ac.uk

Abstract

The British Society for Rheumatology (BSR) established a nationwide register for patients with rheumatological disorders treated with biologic agents. The register is designed as a national prospective study whose primary purpose is to assess long term toxicity from the use of these agents in routine practice. In addition, the data will be capable of addressing the benefits from their use in relation to their toxicity. One specific feature of the BSR register is the recruitment and collection of data from a parallel comparison group, comprising patients with active rheumatoid arthritis treated with conventional disease modifying agents. Both class specific and drug specific analyses of the group treated with biologicals are planned.

  • BSRBR
  • British Society for Rheumatology
  • biological agents
  • rheumatoid arthritis

https://doi.org/10.1136/ard.2005.042499

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • The British Society for Rheumatology Biologics Register (BSRBR) receives financial support from the following UK companies marketing biological agents in the UK: Schering Plough, Wyeth Laboratories, Abbott Laboratories, and Amgen. These resources are used by the BSR to provide a research grant to the University of Manchester.

    • Competing interests: none declared